IGF1 and acromegaly: However, it has been shown for the GHA Pegvisomant that, compared with individuals with acromegaly, mice need approximately 10- to 20-fold higher doses in order to induce a significant reduction of circulating IGF-I (Kopchick et al., 2014; Kopchick et al., 2002).